The pathophysiological consequences of somatostatin receptor internalization and resistance

Related Experiment Video

Updated: Sep 27, 2026

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
09:48

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance

Published on: February 17, 2023

Leo J Hofland1, Steven W J Lamberts

  • 1Department of Internal Medicine, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands. hofland@imw3.fgg.eur.nl

Endocrine Reviews
|February 18, 2003
PubMed

Insights

Somatostatin receptor subtypes influence treatment effectiveness for neuroendocrine tumors. Understanding receptor differences and internalization is key for targeted somatostatin analog therapies.

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • Somatostatin receptors (SSTRs) on tumors are crucial for somatostatin analog therapy in neuroendocrine tumors (NETs).
  • While effective for hormonal control in various NETs, somatostatin analog efficacy varies significantly among patients.
  • This variability may stem from differential expression of SSTR subtypes and their internalization properties.

Purpose of the Study:

  • To review the pathophysiological role of SSTR subtypes in NET treatment efficacy.
  • To discuss the consequences of agonist-induced SSTR internalization for targeted therapies.
  • To explore the development and potential of novel somatostatin analogs.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of somatostatin receptor subtype expression and function.
  • Evaluation of somatostatin analog internalization mechanisms.

Main Results:

  • Differential SSTR subtype expression impacts somatostatin analog efficacy in NETs.
  • Agonist-induced SSTR internalization affects tumor visualization and targeted therapy outcomes.
  • Novel somatostatin analogs show potential for improved therapeutic strategies.

Conclusions:

  • SSTR subtype expression and internalization are critical determinants of somatostatin analog therapy success in NETs.
  • Targeted therapies utilizing somatostatin analogs require consideration of these receptor dynamics.
  • Further research into novel analogs and understanding receptor behavior is warranted.

More Related Videos

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes08:03

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes

Published on: June 25, 2017

Related Concept Videos

Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Receptor-mediated Endocytosis01:20

Receptor-mediated Endocytosis

Receptor-mediated endocytosis is when bulk amounts of specific molecules are imported into a cell after binding to cell surface receptors. The molecules bound to these receptors are taken into the cell through inward folding of the cell surface membrane, which is eventually pinched off into a vesicle within the cell. Structural proteins, such as clathrin, coat the budding vesicle.
Clathrin-Mediated Endocytosis of LDL
One well-characterized example of receptor-mediated endocytosis is the...
Receptor-mediated Endocytosis01:48

Receptor-mediated Endocytosis

Receptor-mediated endocytosis is a process through which bulk amounts of specific molecules can be imported into a cell after binding to cell surface receptors. The molecules bound to these receptors are taken into the cell through inward folding of the cell surface membrane, which is eventually pinched off into a vesicle within the cell. Structural proteins, such as clathrin, coat the budding vesicle and give it its round form.Clathrin-Mediated Endocytosis of LDLOne well-characterized example...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...